Theravance Biopharma, Inc. has announced its first-quarter financial results for 2025, reporting a total revenue of $15.4 million, which is entirely composed of Viatris collaboration revenue. This reflects an increase of $0.9 million, or 6%, compared to the same period in 2024. The company's net loss for the first quarter of 2025 was $13.6 million, compared to $11.7 million in the first quarter of 2024. The non-GAAP net loss from operations was $8.6 million, compared to $4.5 million in the same period in 2024. Theravance Biopharma's cash position stood at $130.9 million as of March 31, 2025. YUPELRI (revefenacin) net sales, recognized by Viatris, amounted to $58.3 million, marking a 6% increase versus the first quarter of 2024. TRELEGY net sales, reported by GSK, rose by 14% to $854 million compared to the same period in the previous year. The company also provided a corporate update, noting that the enrollment for the CYPRESS study is nearing completion, with the final patient expected to be enrolled by late summer. Additionally, Theravance Biopharma reaffirmed all its financial guidance metrics and highlighted its strategic review committee, which continues to evaluate various alternatives to unlock shareholder value.